The Journal of surgical research · 2026
Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dib Youssef E, Connor Ashton A, Todd Jason, Patel Khush A, Elaileh Ahmed, Quigley Eamonn Mm, Simon Caroline J, Cheah Yee Lee, Mobley Constance M, Allenson Kelvin, Esnaola Nestor, Rosenberg Wade R, Abdelrahim Maen, Heyne Kirk E, Dhingra Sadhna, Schwartz Mary R, Moore Linda W, Ghobrial R Mark, Saharia Ashish, Gaber A Osama
Аннотация
INTRODUCTION: Pancreatic adenocarcinoma (PA) has a rising incidence and high mortality, with current overall 5-y survival being less than 15%. Whether outcomes may be improved by the use of neoadjuvant therapy prior to resection is not fully established.
MATERIALS AND METHODS: Data from patients who underwent resection of PA between 2015 and 2024 at a single United States center were retrospectively reviewed. Patient records were stratified by receipt of neoadjuvant therapy (NAT). Outcomes were postresection overall survival, recurrence-free survival, and pathological features at resection.
RESULTS: Between 2015 and 2024, 313 patients underwent resection for PA, of whom 62 (19.8%) received NAT and 229 (73.2%) underwent upfront resection (UFR); 22 (7.0%) patients were excluded due to missing data. Of the 62 NAT patients, three (4.9%) demonstrated complete response on pathological examination, 44 (72%) demonstrated incomplete response, 12 (20%) demonstrated no response, and two had no report (3.1%). The NAT cohort exhibited significantly lower preoperative CA19-9 levels (P < 0.001) and lower T and N stages (P = 0.006 and P < 0.001, respectively), along with reduced rates of perineural and lymphovascular invasion (both P < 0.001). Complete tumor removal with negative margins (R0) was similar between both groups, 49 (79%) in the NAT group versus 169 (74%) in the UFR group (P = 0.4). Neither overall survival nor recurrence-free survival significantly differed between the NAT and UFR groups (hazard ratio= 1.17, 95% confidence interval: 0.76-1.78; hazard ratio= 0.93, 95% confidence intervals: 0.60-1.42, respectively).
CONCLUSIONS: In patients undergoing resection for pancreatic cancer, NAT was associated with less advanced pathologic features at resection, but these did not translate into improved postresection outcomes.
MATERIALS AND METHODS: Data from patients who underwent resection of PA between 2015 and 2024 at a single United States center were retrospectively reviewed. Patient records were stratified by receipt of neoadjuvant therapy (NAT). Outcomes were postresection overall survival, recurrence-free survival, and pathological features at resection.
RESULTS: Between 2015 and 2024, 313 patients underwent resection for PA, of whom 62 (19.8%) received NAT and 229 (73.2%) underwent upfront resection (UFR); 22 (7.0%) patients were excluded due to missing data. Of the 62 NAT patients, three (4.9%) demonstrated complete response on pathological examination, 44 (72%) demonstrated incomplete response, 12 (20%) demonstrated no response, and two had no report (3.1%). The NAT cohort exhibited significantly lower preoperative CA19-9 levels (P < 0.001) and lower T and N stages (P = 0.006 and P < 0.001, respectively), along with reduced rates of perineural and lymphovascular invasion (both P < 0.001). Complete tumor removal with negative margins (R0) was similar between both groups, 49 (79%) in the NAT group versus 169 (74%) in the UFR group (P = 0.4). Neither overall survival nor recurrence-free survival significantly differed between the NAT and UFR groups (hazard ratio= 1.17, 95% confidence interval: 0.76-1.78; hazard ratio= 0.93, 95% confidence intervals: 0.60-1.42, respectively).
CONCLUSIONS: In patients undergoing resection for pancreatic cancer, NAT was associated with less advanced pathologic features at resection, but these did not translate into improved postresection outcomes.